OUR TEAM

Kaitlin Farrell

Partner

Kaitlin Farrell

Partner

Ms. Farrell relies on her technical background, trial experience, and competitive drive to develop results-oriented strategies and achieve favorable outcomes for clients.
Ms. Farrell relies on her technical background, trial experience, and competitive drive to develop results-oriented strategies and achieve favorable outcomes for clients.

OVERVIEW

Kaitlin Farrell is a Partner in the New York office of Haug Partners, where her practice specializes in patent and intellectual property litigation, including pharmaceutical patent litigation under the Hatch-Waxman Act.  Ms. Farrell has successfully litigated matters before various courts and has developed experience in key patent venues such as New Jersey, Delaware, the Western District of Texas, the Federal Circuit, and the U.S. Patent Trials and Appeals Board.  Ms. Farrell’s litigation experience spans a wide array of technologies, including drugs (prodrugs, salts, antihemophilic biologics, peptides, radioligand therapy), medical devices (cardiovascular stents, dental implants), automotive technologies, and mechanical technologies.

REPRESENTATIVE CASES

  • Takeda Pharmaceutical Co. Ltd. et al. v. Norwich Pharmaceuticals Inc., No. 20-8966 (D.N.J. Dec. 27, 2022) (trial victory, nine Orange Book patents covering Takeda’s Vyvanse® held infringed, not invalid, and enforceable)
  • Jens H.S. Nygaard v. Fédération Internationale De L’automobile et al., No. 20-00234 (W.D. Tex.)
  • Barnett v. Surefire Medical, Inc., No. 17-02470 (D. Colo.) (claims of improper inventorship withdrawn after favorable Daubert decision)
  • 3D Scan Guide LLC v. Straumann USA LLC, No. 21-00459 (W.D. Tex.) (infringement claims withdrawn)
  • NOF Corp. v. Nektar Therapeutics. IPR2019-01397, Paper 70 (PTAB Aug. 5, 2021) (key claims to branched-PEG-maleimide polymers not unpatentable)
  • NOF Corp. v. Nektar Therapeutics, IPR2019-01392, Paper 23 (PTAB Feb. 4, 2020) (IPR institution denied for patents directed to PEG polymers)
  • NOF Corp. v. Nektar Therapeutics, IPR2019-01395, Paper 21 (PTAB Feb. 4, 2020) (IPR institution denied for patents directed to PEG polymers)
  • NOF Corp. v. Nektar Therapeutics, IPR2019-01396, Paper 19 (PTAB Feb. 10, 2020) (IPR institution denied for patents directed to PEG polymers)
  • CSL Behring v Shire Viropharma Inc., IPR2019-00459, Paper 8 (PTAB July 2, 2019) (institution denied on patent covering biologic treatment)
  • Shire Orphan Therapies LLC et al v. Fresenius Kabi USA, LLC, No. 15-cv-01102 (D. Del.) (trial victory, asserted Orange Book patent covering Shire’s Firazyr® not invalid for obviousness-type double patenting or unenforceable for prosecution laches)
VIEW ALL

PUBLICATIONS

VIEW ALL

EDUCATION

  • Fordham University (B.S., Biological Sciences and Anthropology, 2013)
  • Notre Dame Law School (J.D., 2017)

BAR ADMISSIONS

  • Registered to Practice before the U.S. Patent and Trademark Office
  • The State Bar of New York
  • Eastern District of New York
  • Court of Appeals for the Federal Circuit
  • District of Colorado
VIEW ALL

MEMBERSHIPS

  • New York Intellectual Property Law Association
  • Federal Circuit Bar Association
  • Women in IP Network (WIN)
  • National Association of Women Lawyers (NAWL)
VIEW ALL

AWARDS

  • American Bar Association and Bloomberg BNA Award for Excellence in the Study of Intellectual Property Law
  • J. Franklin Ewing, SJ, Memorial Award (Fordham University Anthropology Department Honor)
VIEW ALL

CONTACT

LOCATION

New York City
745 Fifth Avenue, 10th Floor,
New York, NY 10151
745 Fifth Avenue, 10th Floor, New York, NY 10151